Rani Therapeutics Q3 2022 net loss $16.2M; cash $98.7M; pipeline progress highlighted

Rani Therapeutics Holdings, Inc.

2022-Q3 EPS reported -$0.93

Cash, cash equivalents, restricted cash equivalents and marketable securities totaled $98.7M at Sept 30, 2022, down from $117.5M at Dec 31, 2021.
Net loss of $16.2M compared to $28.7M in Q3 2021; R&D expenses $9.1M, G&A expenses $7.2M.
RT-102 Phase 1 Part 2 repeat-dose data expected in Q4 2022; positive Part 1 showed 300-400% greater bioavailability vs subcutaneous Forteo.
RT-111 (ustekinumab biosimilar) preclinical development announced; Phase 1 planned in 2023.
$30M committed loan from Avenue Venture Opportunities; up to $150M at-the-market equity offering program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.